Genmab A/S (CPH:GMAB)
3,912.00
+124.00 (3.27%)
Oct 30, 2026, 5:00 PM CET
Genmab Revenue
Genmab had revenue of $1.16B USD in the quarter ending June 30, 2026, with 24.86% growth. This brings the company's total for the last twelve months to $4.13B, up 28.86% year-over-year. In the year 2025, Genmab had annual revenue of $3.72B with 19.19% growth. That makes Genmab the 3,058th largest company in the world by revenue and 16th in Denmark.
Revenue (ttm)
$4.13B
Revenue Growth
+28.86%
P/S Ratio
8.65
Revenue / Employee
$1.32M
Employees
3,119
Market Cap
233.76B DKK
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Genmab breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.72B | 599.00M | 19.19% |
| Dec 31, 2024 | 3.12B | 731.00M | 30.59% |
| Dec 31, 2023 | 2.39B | 302.26M | 14.48% |
| Dec 31, 2022 | 2.09B | 800.56M | 62.19% |
| Dec 31, 2021 | 1.29B | -372.56M | -22.45% |
| Dec 31, 2020 | 1.66B | 854.43M | 106.10% |
| Dec 31, 2019 | 805.32M | 340.75M | 73.35% |
| Dec 31, 2018 | 464.57M | 83.44M | 21.89% |
| Dec 31, 2017 | 381.13M | 123.38M | 47.87% |
| Dec 31, 2016 | 257.75M | 92.65M | 56.12% |
| Dec 31, 2015 | 165.10M | 26.80M | 19.38% |
| Dec 31, 2014 | 138.30M | 15.94M | 13.02% |
| Dec 31, 2013 | 122.37M | 36.66M | 42.78% |
| Dec 31, 2012 | 85.70M | 24.59M | 40.23% |
| Dec 31, 2011 | 61.12M | -43.27M | -41.45% |
| Dec 31, 2010 | 104.39M | -8.77M | -7.75% |
| Dec 31, 2009 | 113.16M | -16.25M | -12.56% |
| Dec 31, 2008 | 129.42M | 25.30M | 24.29% |
| Dec 31, 2007 | 104.12M | 80.20M | 335.29% |
| Dec 31, 2006 | 23.92M | 8.33M | 53.41% |
| Dec 31, 2005 | 15.59M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 329.43B |
| Coloplast | 28.44B |
| H. Lundbeck | 25.96B |
| Demant | 24.63B |
| GN Store Nord | 16.46B |
| ALK-Abelló | 6.83B |
| Embla Medical | 6.56B |
| Bavarian Nordic | 6.34B |
Genmab News
- 16 hours ago - Genmab price target raised to $57 from $42 at Morgan Stanley - TheFly
- 19 hours ago - Genmab price target raised to $80 from $58 at Guggenheim - TheFly
- 1 day ago - Bicara Therapeutics price target lowered to $24 from $33 at Wedbush - TheFly
- 1 day ago - Genmab price target raised to $70 from $50 at H.C. Wainwright - TheFly
- 2 days ago - Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches - MarketBeat
- 2 days ago - Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30% - Nasdaq
- 2 days ago - Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for Its Head and Neck Cancer Treatment - TipRanks
- 2 days ago - Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50% - Barrons